-
公开(公告)号:ECSP10010607A
公开(公告)日:2011-02-28
申请号:ECSP10010607
申请日:2010-11-15
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , PANDEY ANJALI , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR
IPC: A61K31/506 , A61P9/00 , A61P35/00 , C07D239/48 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
Abstract: La presente invención se dirige a compuestos de la Fórmula I-II y tautómeros, sales o estereoisómeros farmacéuticamente aceptables de la misma que son inhibidores de syk y/o JAK quinasas. La presente invención también se dirige a intermediarios usados para realizar dichos compuestos, a la preparación de dicho compuesto, composiciones farmacéuticas que contienen dicho compuesto, métodos de inhibición de syk y/o JAK quinasa, métodos para la inhibición de agregación de plaquetas, y métodos para evitar o tratar una cantidad de enfermedaddes mediadas, al menos en parte, por la actividad syk y/o JAK quinasa, como por ejemplo trombosis y Linfoma no- Hodgkin.
-
公开(公告)号:AU2009244897A2
公开(公告)日:2011-01-20
申请号:AU2009244897
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: MEHROTRA MUKUND , HUANG WOLIN , SONG YONGHONG , JIA ZHAOZHONG J , XU QING , VENKATARAMANI CHANDRASEKAR , BAUER SHAWN M , PANDEY ANJALI , ROSE JACK W , KANE BRIAN
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
-
73.
公开(公告)号:CO6160324A2
公开(公告)日:2010-05-20
申请号:CO09029291
申请日:2009-03-20
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , BAUER SHAWN M , PANDEY ANJALI
IPC: A61K31/536
Abstract: 1.- Un compuesto que tienen la fórmula (I):caracterizado porqueY1 se selecciona a partir del grupo que consiste de N, NH, O, CR5 y CH2; Y2 se selecciona a partir del grupo que consiste de CO, CH2, CH y N, cada R1, R2 y R3 se selecciona independientemente a partir del grupo que consiste de H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -NR72, alcoxi C1-6, halógeno, haloalquilo C1-6, hidroxialquilo C1-6, ciano, -C(O)R6, cicloalquilo C3-6, cicloalquilo C3-6-alquilo C1-6, arilo y arilalquilo C1-6, en donde cada una de dichas porciones alquilo C1-6, alquenilo C2-6, alquinilo C2-6 y arilo, es opcionalmente sustituida con desde 1 hasta 3 sustituyentes, cada uno seleccionado independientemente a partir del grupo que consiste de alquilo C1-6, alquenilo C2-6, alquinilo C2-6, amino, alcoxi C1-6, halógeno, hidroxilo, ciano, oxo, tio, cicloalquilo C3-6, arilo y heteroarilo. R4 es H o -(CH2)mCO2H; R5 se selecciona a partir de H, alquilo C1-6, ciano, halógeno, haloalquilo C1-6, arilo, arilalquilo C1-6 y -C(O)R6;R6 se selecciona a partir del grupo que consiste de H, hidroxi, alquiloC1-6, alcoxi C1-6, heterociclilalcoxi C1-6 y -NR72;cada R7 se selecciona independientemente a partir del grupo que consiste de H, alquilo C1-6 y arilalquilo C1-6 u opcionalmente, dos grupos R7 unidos al nitrógeno son combinados con el átomo de nitrógeno para formar un anillo azetidina, pirrolidina, piperidina o morfolina, en donde cada uno de dicho alquilo C1-6 y arilalquilo C1-C6 es opcionalmente sustituido con desde 1 hasta 3 sustituyentes, cada uno seleccionado independientemente a partir del grupo que consiste de halógeno, amino, hidroxilo, alcoxi C1-6, ciano, alquilo C1-6, cicloalquilo C3-6, arilo, y heteroarilo. cada Ar1 y Ar2 representa un anillo aromático seleccionado a partir del grupo que consiste de benceno, piridina, pirazina, pirimidina, tetrazol y tiofeno, cada uno de los cuales es opcionalmente sustituido con desde 1-2 sustituyentes R8, ...
-
公开(公告)号:HK1131058A1
公开(公告)日:2010-01-15
申请号:HK09110735
申请日:2009-11-17
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , BAUER SHAWN M , PANDEY ANJALI
IPC: A61K20060101 , A61P20060101 , C07D20060101
Abstract: Compounds of formula I are provided: wherein Ar1 and Ar2 are substituted aromatic rings and L1 and L2 are independent divalent linking groups. The compounds are useful as platelet ADP receptor inhibitors, for treating thrombosis and for reducing the likelihood and/or severity of a secondary ischemic event in a patient.
-
公开(公告)号:CA2723205A1
公开(公告)日:2009-12-03
申请号:CA2723205
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR , PANDEY ANJALI
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
-
公开(公告)号:CA2728893A1
公开(公告)日:2009-11-12
申请号:CA2728893
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: VENKATARAMANI CHANDRASEKAR , HUANG WOLIN , MEHROTRA MUKUND , SONG YONGHONG , XU QING , BAUER SHAWN M , PANDEY ANJALI , KANE BRIAN , JIA ZHAOZHONG J , ROSE JACK W
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods ofinhibilion the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as cardiovascular disease, inflammatory disease and autoimune disease and cell proliferative disorder. Formula (I) Y1 is selected from the group consisting of: (a) and (b); Z is O or S; D1 is selected from the group consisting of: (a) phenyl substituted with a group, R5 (b) naphthyl (c) C3-8cycloalkyl (d) heteroaryl (e) heterocyclyl
-
公开(公告)号:CA2960692C
公开(公告)日:2019-09-24
申请号:CA2960692
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR , PANDEY ANJALI
IPC: C07D239/48 , A61K31/505 , A61K31/506 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12
Abstract: The present specification is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present specification is also directed to intermediates used in making such compounds, the preparation of such a compound, methods for inhibition of syk and/or JAK kinase activity, methods for inhibition of the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. The present specification is also directed to pharmaceutical compositions containing such a compound and which are formulated for topical administration.
-
公开(公告)号:CY1118559T1
公开(公告)日:2017-07-12
申请号:CY161101026
申请日:2016-10-13
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR , PANDEY ANJALI
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
Abstract: ΗπαρούσαεφεύρεσηαναφέρεταισεενώσειςτουτύπουΙ-ΙΙκαιταφαρμακευτικάαποδεκτάταυτομερή, άλατα, ήταστερεοϊσομερήαυτών, ταοποίαείναιαναστολείςτηςκινάσης Syk και/ή JAK. Ηπαρούσαεφεύρεσηεπίσηςαναφέρεταισεενδιάμεσαπουχρησιμοποιούνταιστηνσύνθεσητέτοιωνενώσεων, τηνπαρασκευήμίαςτέτοιαςένωσης, τιςφαρμακευτικέςσυνθέσειςπουπεριέχουνμίατέτοιαένωση, τιςμεθόδουςαναστολήςτηςδραστικότηταςτηςκινάσης Syk και/ή JAK, τιςμεθόδουςαναστολήςτηςσυσσωμάτωσηςτωναιμοπεταλίων, καιτιςμεθόδουςγιατηνπρόληψηή τηθεραπείαενόςαριθμούπαθήσεωνπουπροκαλούνταιτουλάχιστονενμέρειαπότηνδραστικότητατηςκινάσης Syk και/ή JAK, όπωςη καρδιαγγειακήνόσος, ηφλεγμονώδηςνόσος, ηαυτοάνοσηνόσοςκαιη πολλαπλασιαστικήδιαταραχήκυττάρων, ηθρόμβωση, ηαλλεργία, τοάσθμα, ηρευματοειδήςαρθρίτιδα, ηλευχαιμία, ήτολέμφωμαμη-Hodgkin.
-
公开(公告)号:CA2723205C
公开(公告)日:2017-03-14
申请号:CA2723205
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR , PANDEY ANJALI
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
Abstract: The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation,and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.
-
公开(公告)号:LT2321283T
公开(公告)日:2016-12-12
申请号:LT09755219
申请日:2009-04-16
Applicant: PORTOLA PHARM INC
Inventor: BAUER SHAWN M , JIA ZHAOZHONG J , SONG YONGHONG , XU QING , MEHROTRA MUKUND , ROSE JACK W , HUANG WOLIN , VENKATARAMANI CHANDRASEKAR , PANDEY ANJALI
IPC: C07D239/48 , A61K31/506 , A61P9/00 , A61P35/00 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
-
-
-
-
-
-
-
-
-